5PSQ-031 Evaluation of the safety and tolerance of the commercial presentation of cyclosporine 0.1% collyrium

Autor:	AM Martínez Soto, M Garcia Coronel, P Ortiz Fernandez, JM Marco Puig, C Pastor Mondéjar, P Fernandez-Villacañas Fernandez, L Rentero Redondo, C Caballero Requejo, C Iniesta Navalon, I Salar Valverde, E Urbieta Sanz
Rok vydání:	2022
Zdroj:	Section 5: Patient safety and quality assurance.
DOI:	10.1136/ejhpharm-2022-eahp.268
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7dd7f44ab467d641390b1e46d643ce0c https://doi.org/10.1136/ejhpharm-2022-eahp.268 Zobrazit plný text záznamu